BioCentury | Apr 28, 2017
Clinical News

Serelaxin: Development discontinued

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Mar 24, 2017
Clinical News

Serelaxin: Ph III RELAX-AHF-2 data

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | May 26, 2014
Clinical News

Reasanz serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | May 19, 2014
Clinical News

Serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Apr 7, 2014
Regulation

Breakthrough in action

...year, are expected in 2016. Serelaxin's effect Novartis gained serelaxin in its 2010 acquisition of Corthera Inc....
BioCentury | Mar 31, 2014
Clinical News

Serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Mar 10, 2014
Clinical News

Serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Jan 27, 2014
Clinical News

Serelaxin regulatory update

...to the product under a 1999 deal with Corthera Inc. , which Novartis acquired in 2010. Corthera...
BioCentury | Jan 13, 2014
Clinical News

Serelaxin regulatory update

...to the product under a 1999 deal with Corthera Inc. , which Novartis acquired in 2010. Corthera...
BioCentury | Dec 9, 2013
Clinical News

Serelaxin regulatory update

...to the product under a 1999 deal with Corthera Inc. , which Novartis acquired in 2010. Corthera...
Items per page:
1 - 10 of 28
BioCentury | Apr 28, 2017
Clinical News

Serelaxin: Development discontinued

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Mar 24, 2017
Clinical News

Serelaxin: Ph III RELAX-AHF-2 data

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | May 26, 2014
Clinical News

Reasanz serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | May 19, 2014
Clinical News

Serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Apr 7, 2014
Regulation

Breakthrough in action

...year, are expected in 2016. Serelaxin's effect Novartis gained serelaxin in its 2010 acquisition of Corthera Inc....
BioCentury | Mar 31, 2014
Clinical News

Serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Mar 10, 2014
Clinical News

Serelaxin regulatory update

...which had the rights under a 1999 deal with Corthera Inc. In 2010, Novartis acquired Corthera...
BioCentury | Jan 27, 2014
Clinical News

Serelaxin regulatory update

...to the product under a 1999 deal with Corthera Inc. , which Novartis acquired in 2010. Corthera...
BioCentury | Jan 13, 2014
Clinical News

Serelaxin regulatory update

...to the product under a 1999 deal with Corthera Inc. , which Novartis acquired in 2010. Corthera...
BioCentury | Dec 9, 2013
Clinical News

Serelaxin regulatory update

...to the product under a 1999 deal with Corthera Inc. , which Novartis acquired in 2010. Corthera...
Items per page:
1 - 10 of 28